Federated Hermes, Inc. C4 Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$4.05 - $8.1 $1,279 - $2,559	316 New	316 $1,000
Q3 2023 Nov 13, 2023	BUY	$1.81 - $3.89 $4,957 - $10,654	2,739 Added 681.34%	3,141 $5,000
Q2 2023 Aug 14, 2023	SELL	$2.75 - $3.77 $8,401 - $11,517	-3,055 Reduced 88.37%	402 $1,000
Q1 2023 May 08, 2023	SELL	$3.1 - $9.02 $23,603 - $68,678	-7,614 Reduced 68.77%	3,457 $10,000
Q4 2022 Feb 13, 2023	BUY	$5.42 - $10.24 $54,611 - $103,178	10,076 Added 1012.66%	11,071 $65,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $7,989 - $12,706	995 New	995 $9,000
Q1 2022 May 13, 2022	SELL	$19.99 - $33.23 $837,521 - $1.39 Million	-41,897 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$29.39 - $46.86 $491,253 - $783,264	-16,715 Reduced 28.52%	41,897 $1.35 Million
Q3 2021 Nov 15, 2021	BUY	$35.91 - $50.5 $2.1 Million - $2.96 Million	58,612 New	58,612 $2.62 Million
Q2 2021 Aug 16, 2021	SELL	$30.39 - $42.18 $1.18 Million - $1.64 Million	-38,975 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$31.96 - $46.5 $1.25 Million - $1.81 Million	38,975 New	38,975 $1.44 Million

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $178M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.